Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Regeneron Pharmaceuticals, Inc shares valued at $844,610 were sold by McCourt Marion on Nov 01 ’24. At $844.61 per share, McCourt Marion sold 1,000 shares. The insider’s holdings dropped to 12,931 shares worth approximately $10.56 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, MARION E MCCOURT purchased 1,000 shares, netting a total of over 844,610 in proceeds.
Before that, RYAN ARTHUR F had sold 100 shares from its account. In a trade valued at $104,878, the Director traded Regeneron Pharmaceuticals, Inc shares for $1048.78 each. Upon closing the transaction, the insider’s holdings decreased to 100 shares, worth approximately $14.36 million.
As published in a research note from Leerink Partners on September 24, 2024, Regeneron Pharmaceuticals, Inc [REGN] has been rated down from an Outperform to a Market perform and the price target has been revised to $1077 from $1175. Analysts at Bernstein started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid March. As of January 12, 2024, RBC Capital Mkts has increased its “Sector perform” rating to a “an Outperform” for REGN. Earlier on November 09, 2023, Deutsche Bank initiated its rating. Their recommendation was “a Hold” for REGN stock.
Analyzing REGN Stock Performance
During the last five days, there has been a drop of approximately -11.50%. Over the course of the year, Regeneron Pharmaceuticals, Inc shares have dropped approximately -7.02%. Shares of the company reached a 52-week high of $1,211.20 on 08/27/24 and a 52-week low of $813.53 on 11/06/24. A 50-day SMA is recorded $1,036.21, while a 200-day SMA reached $1,011.52. Nevertheless, trading volume fell to 0.88 million shares from 0.63 million shares the previous day.
Support And Resistance Levels for Regeneron Pharmaceuticals, Inc (REGN)
According to the 24-hour chart, there is a support level at 805.28, which, if violated, would cause prices to drop to 793.92. In the upper region, resistance lies at 836.26. The next price resistance is at 855.88. RSI (Relative Strength Index) is 12.99 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -79.33, which suggests the price will decrease in the coming days. Percent R is at 98.35%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
